Search

Your search keyword '"Bobos M"' showing total 10 results
Start Over Author "Bobos M" Journal cancer research
10 results on '"Bobos M"'

1. Abstract P4-08-13: Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs) in patients with early breast cancer (EBC) treated with dose-dense sequential adjuvant chemotherapy (dds-CT). An observational study (ACTRN12616001043426)

Author

Kourea, HP, primary, Koletsa, T, additional, Kotoula, V, additional, Koliou, G-A, additional, Batistatou, A, additional, Pentheroudakis, G, additional, Arapantoni-Dadioti, P, additional, Zagouri, F, additional, Bobos, M, additional, Sotiropoulou, M, additional, Papoudou-Bai, A, additional, Chrisafi, S, additional, Efstratiou, I, additional, Aravantinos, G, additional, Nicolaou, I, additional, Gogas, H, additional, Visvikis, A, additional, Christodoulou, C, additional, Petraki, C, additional, Koutras, A, additional, Psyrri, A, additional, Pectasides, D, additional, and Fountzilas, G, additional

Published
2019
Full Text
View/download PDF

2. Abstract P6-09-07: Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer

Author

Kotoula, V, primary, Giannoulatou, E, additional, Kouvatseas, G, additional, Tikas, I, additional, Lazaridis, G, additional, Charalambous, E, additional, Efstratiou, I, additional, Bobos, M, additional, Tsolaki, E, additional, Zagouri, F, additional, Christodoulou, C, additional, Pentheroudakis, G, additional, Koutras, A, additional, Papakostas, P, additional, Kosmidis, PA, additional, Pectasides, D, additional, and Fountzilas, G, additional

Published
2017
Full Text
View/download PDF

3. Abstract P5-08-50: Associations of MYC protein expression and gene status with breast cancer subtypes and outcome in patients treated with anthracycline-based adjuvant chemotherapy

Author

Batistatou, A, primary, Razis, E, additional, Bobos, M, additional, Tsolaki, E, additional, Timotheadou, E, additional, Alexopoulou, Z, additional, Goussia, A, additional, Gogas, H, additional, Koutras, A, additional, Karina, M, additional, Pentheroudakis, G, additional, Efstratiou, I, additional, Petraki, K, additional, Sotiropoulou, M, additional, Pavlakis, K, additional, Koletsa, T, additional, Kotoula, V, additional, and Fountzilas, G, additional

Published
2016
Full Text
View/download PDF

4. Abstract P4-14-05: Genomic parameters affecting the outcome of patients with advanced breast cancer treated with trastuzumab

Author

Gogas, H, primary, Kotoula, V, additional, Alexopoulou, Z, additional, Christodoulou, C, additional, Kostopoulos, I, additional, Bobos, M, additional, Raptou, G, additional, Charalambous, E, additional, Tsolaki, E, additional, Xanthakis, I, additional, Pentheroudakis, G, additional, Koutras, A, additional, Bafaloukos, D, additional, Papakostas, P, additional, Aravantinos, G, additional, Psyrri, A, additional, Petraki, K, additional, Kalogeras, KT, additional, Fountzilas, G, additional, and Pectasides, D, additional

Published
2016
Full Text
View/download PDF

7. PD05-02: Effect of HER2/Topoisomerase II alpha (TOP2A) Gene Status or Protein Expression and Chromosome 17 (CEP17) Polysomy on the Outcome of Breast Cancer Patients Treated with Anthracycline-Containing Dose-Dense Sequential Adjuvant Chemotherapy with or without Paclitaxel – A Pooled Analysis of Two Hellenic Cooperative Oncology Group (HeCOG) Phase III Trials.

Author

Dafni, U, primary, Bobos, M, additional, Tsolaki, E, additional, Batistatou, A, additional, Koletsa, F, additional, Televantou, D, additional, Gogas, H, additional, Linardou, H, additional, Pectasides, D, additional, Kalogeras, KT, additional, Galani, E, additional, Koutras, A, additional, Papadimitriou, CA, additional, and Fountzilas, G, additional

Published
2011
Full Text
View/download PDF

9. Evaluation of the Predictive Value of IGF-IRa, IGF-IRb, UPA, and PAI-1 in Patients with Advanced Breast Cancer (ABC) Treated with Trastuzumab.

Author

Kostopoulos, I., primary, Karayannopoulou, G., additional, Bobos, M., additional, Skarlos, D., additional, Briassoulis, E., additional, Koutras, A., additional, Pectasides, D., additional, Linardou, H., additional, Razis, E., additional, Matsiakou, F., additional, Kalogeras, K., additional, and Fountzilas, G., additional

Published
2009
Full Text
View/download PDF

10. Revisiting chromosome 17q copy number aberrations in early high-risk breast cancer.

Author

Kotoula, V., Bobos, M., Eleftheraki, A. G., Timotheadou, E., Razis, E., Goussia, A., Levva, S., Kalogeras, K. T., Pectasides, D., and Fountzilas, G.

Subjects
*BREAST cancer research, *HER2 gene, *FLUORESCENCE in situ hybridization, *CHROMOSOMES, *CANCER risk factors
Abstract

Background -- Aim: HER2 and TOP2A gene status are of prognostic/predictive relevance and are broadly determined with fluorescent in situ hybridization (FISH). For this purpose, probes against (A) 17p11.1-q11.1 (>5Mb, CENtromere), (B) 17q12 (600Kb, including HER2 among other genes), and (C) 17q21-22 (500Kb, similarly including TOP2A) are used, and gene pathology is determined by B/A and C/A signal ratios according to consensus cut-offs. However, chromosome 17 (chr17) and 17q pathology is complex and may be misinterpreted by this approach, especially in cases with low copy gains. Herein, we profiled A, B and C signals in 1027 adjuvantly treated, early breast cancer patients. Methods: Maximal A, B, C copy numbers (raw FISH data) were submitted to hierarchical clustering as continuous variables. Clusters were compared with clinicopathological parameters, conventional FISH ratios, and were evaluated for their prognostic significance (overall survival, OS) with respect to tumor Ki67 status (13% cut-off), TopoIIa protein (5% cut- off) and ER/PgR positivity (1% cut-off). Results: Clustered values resulted into 832 (81%) putatively chr17 stable tumors (ABClow) and 195 17q unstable tumors. Out of these, 43 (4%) had possible chr17 gain (ABChigh), 30 (3%) HER2/TOP2A gain (BChigh), and 122 (12%) HER2 gain (Bhigh). Unstable 17q was more frequent in Ki67 high, ER/PgR negative, high-grade tumors, and were almost exclusively present in luminal-HER2 and HER2-enriched tumors (all Pearson's p's<0.001). Concordance of ABChigh, BChigh and Bhigh with the respective classical CEN17, HER2/TOP2A and HER2 gains was overall <50%, but it was 93-100% in high copy cases. Significant interactions of ABChigh, BChigh and Bhigh copy profiles with Ki67 status (Wald's p = 0.007) and TopoIIa immunopositivity (Wald's p = 0.018) were observed. Among patients with low Ki67 tumors, 5- year survival rates were 95% Bhigh, 90% ABClow, 88% ABChigh and 63% BChigh (BChigh vs. ABClow, HR=3.65, 95%CI 1.32-10.09, p = 0.013), while among patients with high Ki67, no such difference was observed. Similarly, patients with TopoIIa negative - BChigh tumors were associated with shorter OS (HR = 2.63, 95%CI 1.06-6.48, p = 0.036) compared to ABClow tumors. By contrast, the interaction observed between copy profiles and ER/PgR status (Wald's p = 0.011) was in the opposite direction. Among patients with ER/PgR negative tumors, those with BChigh and ABChigh tumors survived longer than those with ABClow tumors (HR = 0.29, 95%CI 0.12-0.73, p = 0.008); no such difference was observed in ER/PgR positive tumors. Conclusions: Profiles of 17p11-q11, 17q12 and 17q21-22 copies according to broadly used FISH probes reveal distinct subgroups of breast cancer with possibly different versions of chromosomal instability that are only partially concordant with classical CEN17, HER2 and TOP2A gain status. The prognostic significance of these profiles seems to depend on tumor proliferation and hormonal status, as well as on the extent of the affected areas on 17q. Validation of these profiles for prospective application may aid in a more accurate assessment of early high-risk breast cancer patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results